Descripción de la empresa
Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutics specifically designed to treat retinal diseases. The company functions within the healthcare sector, more precisely categorized under the biotechnology industry, where it focuses on advancing proprietary drug candidates through various stages of clinical validation. According to available data, the organization employs approximately 124 individuals and maintains a total market capitalization of $2.58 billion. While the company's trailing twelve-month revenue is not disclosed in the provided financial records, its market valuation indicates a significant investor interest relative to its current operational scale and workforce size. The substantial market cap of $2.58 billion suggests that the market assigns a high valuation premium to the company's pipeline, particularly its lead product candidate tarcocimab tedromer, despite the absence of reported annual revenue figures in this specific dataset.
Salud financiera
The financial statements for Kodiak Sciences Inc. report a net income of $-229,967,000 and an EBITDA of $-216,060,000 over the trailing twelve months, while the specific revenue figure is not available for calculation. The substantial gap between the reported net income loss and the EBITDA figure reveals a significant cost structure driven by interest expenses or other non-operational costs that erode profitability before reaching the bottom line. The company generated a free cash flow of $-44,382,500, indicating that it is currently burning cash, which limits its immediate financial flexibility to fund operations without further external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the typical accounting treatment for early-stage biotechnology firms that have not yet achieved commercial revenue streams to generate traditional margins. On the liability side, the company holds $209.86 million in cash and cash equivalents against $59.18 million in debt, resulting in a debt-to-equity ratio of 37.60. Although the company carries debt, the available cash balance significantly exceeds total obligations, suggesting a balance sheet that remains robust despite the negative leverage ratio often seen in growth-stage companies. Liquidity is further supported by a current ratio of 4.72, which indicates a strong ability to meet short-term obligations with its existing assets. Furthermore, the return on equity stands at -149.5% and the return on assets is -42.6%, metrics that mathematically reflect the dilutive impact of losses on the company's shareholder equity and total asset base rather than operational inefficiency.
Evaluación de valoración
Valuation metrics for Kodiak Sciences Inc. present a complex picture due to the lack of positive earnings; the trailing P/E ratio is listed as N/A, while the forward P/E is -12.23. The negative forward P/E implies that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term, rendering traditional earnings-based valuation multiples inapplicable. Instead, investors rely on the price-to-book ratio of 16.37, which indicates that the stock trades at a significant premium relative to its net book value, a common characteristic for companies with valuable intellectual property that is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also reported as N/A or -11.24, further highlighting the reliance on asset-based or clinical-stage valuation methodologies rather than cash-flow or earnings multiples. The stock has experienced extreme volatility, with a 52-week high of $45.60 and a 52-week low of $1.92, illustrating a wide trading range that captures significant market sentiment shifts. With a beta of 2.40, the stock exhibits high price volatility, moving with more than double the magnitude of the broader market index.
Growth & Income
Growth metrics for Kodiak Sciences Inc. are not quantified in the current dataset, as both revenue growth year-over-year and earnings growth year-over-year are listed as N/A. Consequently, it is impossible to calculate a growth rate to determine if earnings are growing faster or slower than revenue, as the underlying revenue baseline is not provided. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute profits to shareholders but instead retains all capital to fund research and development. This reinvestment strategy is typical for clinical-stage biopharmaceutical firms that prioritize pipeline advancement over income generation. The overall growth and income profile for Kodiak Sciences Inc. is characterized by a focus on capital preservation and pipeline development rather than current profitability or dividend distributions, as evidenced by the zero payout ratio and the absence of reported revenue growth figures.